What is EnsiliTech?
EnsiliTech is a pioneering biotechnology enterprise focused on the development of its patented Ensilication technology. This breakthrough platform utilizes a temperature-stable silica matrix to protect sensitive biological materials, including vaccines, enzymes, and antibodies. By eliminating the reliance on energy-intensive cold-chain logistics, the company addresses one of the most significant bottlenecks in the global distribution of life-saving therapeutics. Its market position is defined by its ability to enhance the accessibility and stability of biopharmaceuticals, particularly in resource-constrained environments where refrigeration infrastructure is often unreliable or unavailable.
How much funding has EnsiliTech raised?
EnsiliTech has raised a total of $7.5M across 2 funding rounds:
Other Financing Round
$1.4M
Seed
$6M
Other Financing Round (2023): $1.5M with participation from Science Angel Syndicate, QantX, Elbow Beach Capital, UK Research & Innovation, and Fink Family Law Offices
Seed (2025): $6M led by Calculus Capital, Fink Family Law Offices, Eos Advisory, and QantX
Key Investors in EnsiliTech
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology and healthcare sectors.
Eos Advisory
Eos is a Scottish investment firm that bridges innovation with global opportunities by investing in and commercializing science and technology, with a strong emphasis on environmental sustainability and disease diagnostics.
QantX
QantX is dedicated to transforming the spinout landscape in the South West UK by providing early-stage founders with local capital and commercial expertise in the biotech and advanced materials sectors.
What's next for EnsiliTech?
Looking ahead, the strategic deployment of this capital will likely focus on scaling manufacturing capabilities and expanding the application of the Ensilication platform across diverse therapeutic classes. As the company moves deeper into its growth phase, the focus will shift toward regulatory validation and establishing strategic partnerships with global pharmaceutical distributors. By mitigating the risks associated with temperature fluctuations during transit, EnsiliTech is poised to become a foundational player in the future of global health security and sustainable biopharmaceutical supply chains.
See full EnsiliTech company page
